Next-generation Models for the PK Evaluation of Antibody and Albumin-Conjugated Drug Candidates

The following presentations from our April 2025 virtual event demonstrate how JAX's humanized models enable rational selection of the best lead therapeutic candidates, with equivalent or better predictive ability than nonhuman primates for human pharmacokinetics.

Event Presentations

over 1 year ago

Biology-Guided Design of Human Albumin Fusions

Presented by Jan Terje Andersen, Ph.D., Professor in Biomedical Innovation, University of Oslo

Watch Video

9 months ago

Humanized FcRn Mouse Model for Evaluating PK and Allometric Scaling

Presented by Michael Kiffe, Ph.D., Director PK Sciences / Translational Medicine, & Monika Gajewska, Ph.D., M&S Group, PK Sciences, Novartis Pharma AG

Watch Video

Error - something went wrong!

Ready to discuss your needs with our experts?

Thank you, we will be in touch soon!

9 months ago

Enhancing Antibody Development: Leveraging FcRn Transgenic Mice (tg32) for Drug Discovery of Therapeutic Antibodies

Presented by Martin Lechmann Ph.D., DMPK/PD Project Lead (DPL) Biologics, Roche Diagnostics GmbH

Watch Video

over 1 year ago

Q&A Highlights

Additional Resources

about 1 year ago

HuPK™: A Humanized Platform for therapeutic antibody PK evaluation

over 4 years ago

Preclinical Drug Development Fact Sheet

A glimpse at the wide range of platforms and services JAX offers to help move you from drug discovery to IND filing.

over 7 years ago

Revealing antibody half-life and stability using FcRn mouse models from JAX

The approval of Orthoclone OKT3® (muromonab-CD3) in 1986 marked the first appearance of monoclonal antibodies in the clinic. In the over 20 years since, more than 70 antibodies have been approved...

Learn More